Business
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
TORONTO and HOUSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&#...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference\n\n\n\n TORONTO and HOUSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in the ROTH 4\n \n th\n \n Annual Healthcare Opportunities Conference\n \n ,\n \n taking place at the Metropolitan Club in New York City on October 8-9, 2025.\n \n\n\n Event Details:\n \n\n\n\n\n Conference:\n \n ROTH 4\n \n th\n \n Annual Healthcare Opportunities Conference\n \n\n\n Date:\n \n October 8-9\n \n th\n \n , 2025\n \n\n\n Format:\n \n 1x1/small group meetings with institutional investors\n \n\n\n Location:\n \n Metropolitan Club, New York, NY\n \n\n\n This format featuring 1-on-1 and small group meetings will offer institutional investors with extensive interaction with executive management to gain in-depth insights into each company. To learn more and submit a registration request, visit\n \n https://www.roth.com/healthcareopportunities\n \n\n\n\n About ROTH\n \n\n ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Its full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately held, employee-owned organization and maintains offices throughout the U.S.\n \n\n For more information, visit:\n \n https://www.roth.com\n \n\n\n\n About Medicenna Therapeutics\n \n\n\n Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, biza...